For the sequential administration of targeted therapy and immunotherapy, two independent trials (Dreamseq, Secombit) came to the same conclusion that immunotherapy followed by the continuation of BRAF/MEK-targeted therapy could be the most beneficial for individuals with advanced melanoma harboring BRAF mutations [86,87]. The gene discussed is MAP2K7; the disease is melanoma.